Sign In

Search Press
Looking for press releases of a particular company? Enter company name (or keyword) here.


NOXXON Pharma announces appointment of Lawrence E. Posner to its board of directors

Berlin, Germany July 08, 2008 -- NOXXON Pharma AG (NOXXON), developer of mirror image oligonucleotide therapeutics termed Spiegelmers®, announced today the appointment of Lawrence E. Posner, MD, to its Board of Directors.

Dr. Posner brings to NOXXON over 25 years of experience in pharmaceutical research and development. He has held executive R & D positions with Yamanouchi Pharma America, Inc., Bayer’s Pharmaceutical Division, and the Medical Research Division of Lederle Laboratories, among others. From 1988 to 2003 Dr. Posner held a number of key leadership roles at Bayer’s Pharmaceutical Division, most recently as Senior Vice President, Pharmaceutical Development and Worldwide Head of Regulatory Affairs. During the course of his distinguished career Dr. Posner has been involved in the development and registration of 18 new drugs.

'We are privileged to have such a knowledgeable and accomplished industry leader as Dr. Posner join our Board,' commented Dr. Frank Morich, NOXXON’s Chief Executive Officer. 'Dr. Posner’s broad experience in the pharmaceutical industry especially his international clinical expertise make him a valuable addition to our Board of Directors. His extensive experience in regulatory affairs will be highly beneficial to NOXXON as we continue to rapidly advance Spiegelmers® into the clinic and beyond.'

Dr. Posner commented on his appointment: 'NOXXON’s Spiegelmers® are a unique substance class and have excellent potential as therapeutics for the treatment of a variety of diseases. In my role as an active member of NOXXON’s Board of Directors I look forward to contributing to the company’s ongoing efforts to bring Spiegelmers from the laboratory to patients.”

A graduate of Brandeis University, Dr. Posner earned his MD at Case Western Reserve University and later specialized in medical oncology and tumor virology while working at the National Cancer Institute in Washington, DC, in the Laboratory of Tumor Cell Biology under Dr. Robert Gallo. He spent three years in private practice in Long Beach, California, before he began his successful career in the pharmaceutical industry. In 2004 he returned briefly to academics and received a Master’s Degree in Economics from the University of Connecticut in 2006. Dr. Posner currently serves on the Board of Directors of Labopharm, Inc. of Laval, Quebec, and is a member of the Board of Visitors of Case Western Reserve University School of Medicine. He is a general partner at Vedanta Capital in New York City, NY.

About NOXXON Pharma AG:

Based on one of best protected technology platforms in the industry, NOXXON Pharma AG develops biostable aptamers, novel substances using mirror image nucleic acids. These so-called Spiegelmers® (the German word “Spiegel” means mirror) are highly specific for the pharmacologically relevant target for which they were selected. Thanks to their structural characteristics, Spiegelmers® are extremely resistant to degradation and not immunogenic - a new generation of improved therapeutics.

Website info:

General contact: Emmanuelle Delabre

Max-Dohrn-Strasse 8-10
10589 Berlin, Germany

Phone: + 49 30 72 62 47 0
FAX: + 49 30 72 62 47 225

Publisher Contact Information:

Noxxon Pharma AG
+ 49 30 72 62 47 0

Company profile of Noxxon Pharma AG
Past press releases of Noxxon Pharma AG.


Tech investments
From our Online Data Service
VC-backed companies
From our Radar

Recent Deals

Aug 19€7.0MAgriculture related
Aug 19€9.0MInternet commerce
Aug 19€10.0ME-Commerce
Aug 19€63.0MBusiness applications
Aug 16€16.0ME-Commerce
Aug 16€6.0MBusiness applications
Aug 16N/ASoftware development

For information on Europe's most extensive database on technology funding click here!


Press Releases

May 28
identiq raises $5m seed, launches privacy-first identity validation...

Apr 29
nethone raised over $1 million from innovation nest

Oct 1
The Link App
the link app launches version 2.0

Mar 29
Addex Therapeutics
addex sucessfully raises chf40 million in capital increase

Jan 2
Urban Jungle
urban jungle raises £1m in seed funding to build tech-enabled home ...

About usContact usLegal Information
Copyright © 1999-2019
Emerging Technology Research Europe Inc. All rights reserved.